To improve excellence in the diagnosis and treatment of venous and lymphatic disorders as long as patient-centered care focusing on improving patient outcomes.
To make UIP World Congress as the most prestigious global phlebology gathering and organize other live or online meetings to increase the scientific dominance of UIP.
To correct UIP's financial deterioration immediately: Starting from 1960 France meeting, the total payment of the Countries to UIP except Istanbul was 109.030 USD. Turkish Society alone paid 2 times more than all UIP meetings following 2022 UIP Istanbul world Congress, which is 206.042 USD. That can be achieved with a critical calculation of incomes and expenses to survive! This is the main reason of the resignation of the UIP elected treasurer, Paul Thibault, on 07.06.2024. All candidates in this group are committed to prioritize the interests of UIP over private foundations or associations in this regard. The executive committee candidates have organized many national and international congresses for many years worldwide and have huge experience. We aim to bring UIP economically strong union provided a scientific, respectful relation with phlebology world and the related industry partners.
To foster collaboration among 81 member societies, ensuring that UIP's leadership reflects a diverse and inclusive perspective for addressing global challenges in phlebology.
To elect committee members who are committed to providing access to high-quality education, training, and resources for current and future medical professionals in the field of phlebology. We aim to promote online learning platforms as webinars, case-based learning, online certification and UIP-endorsed fellowships.
To ensure that elections and leadership structures are conducted with the highest ethical standards, transparency, and accountability.
To lead International guidelines in venous and lymphatic disease as classification systems, diagnostic standards, treatment techniques, compression therapy, venous ulcer management, pelvic venous disorders and venous thromboembolism.
To collaborate with companies like producing sclerosing agents, catheters, compression devices, ablation technologies, or phlebology imaging equipment to fund clinical trials that encourages innovation and evidence-based advancement.